These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 36347314)

  • 1. The first structure-activity relationship study of oxytocin as a positive allosteric modulator for the µ opioid receptor.
    Mizuguchi T; Miyano K; Yamauchi R; Yoshida Y; Takahashi H; Yamazaki A; Ono H; Inagaki M; Nonaka M; Uezono Y; Fujii H
    Peptides; 2023 Jan; 159():170901. PubMed ID: 36347314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropeptide oxytocin enhances μ opioid receptor signaling as a positive allosteric modulator.
    Meguro Y; Miyano K; Hirayama S; Yoshida Y; Ishibashi N; Ogino T; Fujii Y; Manabe S; Eto M; Nonaka M; Fujii H; Ueta Y; Narita M; Sata N; Yada T; Uezono Y
    J Pharmacol Sci; 2018 May; 137(1):67-75. PubMed ID: 29716811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxytocin Is a Positive Allosteric Modulator of κ-Opioid Receptors but Not δ-Opioid Receptors in the G Protein Signaling Pathway.
    Miyano K; Yoshida Y; Hirayama S; Takahashi H; Ono H; Meguro Y; Manabe S; Komatsu A; Nonaka M; Mizuguchi T; Fujii H; Higami Y; Narita M; Uezono Y
    Cells; 2021 Oct; 10(10):. PubMed ID: 34685631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive allosteric modulation of the mu-opioid receptor produces analgesia with reduced side effects.
    Kandasamy R; Hillhouse TM; Livingston KE; Kochan KE; Meurice C; Eans SO; Li MH; White AD; Roques BP; McLaughlin JP; Ingram SL; Burford NT; Alt A; Traynor JR
    Proc Natl Acad Sci U S A; 2021 Apr; 118(16):. PubMed ID: 33846240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medications.
    Burford NT; Traynor JR; Alt A
    Br J Pharmacol; 2015 Jan; 172(2):277-86. PubMed ID: 24460691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disruption of the Na+ ion binding site as a mechanism for positive allosteric modulation of the mu-opioid receptor.
    Livingston KE; Traynor JR
    Proc Natl Acad Sci U S A; 2014 Dec; 111(51):18369-74. PubMed ID: 25489080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of selective agonists and positive allosteric modulators for µ- and δ-opioid receptors from a single high-throughput screen.
    Burford NT; Wehrman T; Bassoni D; O'Connell J; Banks M; Zhang L; Alt A
    J Biomol Screen; 2014 Oct; 19(9):1255-65. PubMed ID: 25047277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational insights into the molecular mechanisms of differentiated allosteric modulation at the mu opioid receptor by structurally similar bitopic modulators.
    Wang H; Reinecke BA; Zhang Y
    J Comput Aided Mol Des; 2020 Aug; 34(8):879-895. PubMed ID: 32193867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positive allosteric modulation of the cannabinoid type-1 receptor (CB1R) in periaqueductal gray (PAG) antagonizes anti-nociceptive and cellular effects of a mu-opioid receptor agonist in morphine-withdrawn rats.
    Datta U; Kelley LK; Middleton JW; Gilpin NW
    Psychopharmacology (Berl); 2020 Dec; 237(12):3729-3739. PubMed ID: 32857187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive allosteric modulation of endogenous delta opioid receptor signaling in the enteric nervous system is a potential treatment for gastrointestinal motility disorders.
    DiCello JJ; Carbone SE; Saito A; Pham V; Szymaszkiewicz A; Gondin AB; Alvi S; Marique K; Shenoy P; Veldhuis NA; Fichna J; Canals M; Christopoulos A; Valant C; Poole DP
    Am J Physiol Gastrointest Liver Physiol; 2022 Jan; 322(1):G66-G78. PubMed ID: 34755545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor.
    Burford NT; Clark MJ; Wehrman TS; Gerritz SW; Banks M; O'Connell J; Traynor JR; Alt A
    Proc Natl Acad Sci U S A; 2013 Jun; 110(26):10830-5. PubMed ID: 23754417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligand-Based Discovery of a New Scaffold for Allosteric Modulation of the μ-Opioid Receptor.
    Bisignano P; Burford NT; Shang Y; Marlow B; Livingston KE; Fenton AM; Rockwell K; Budenholzer L; Traynor JR; Gerritz SW; Alt A; Filizola M
    J Chem Inf Model; 2015 Sep; 55(9):1836-43. PubMed ID: 26347990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation mechanism of the μ-opioid receptor by an allosteric modulator.
    Kaneko S; Imai S; Asao N; Kofuku Y; Ueda T; Shimada I
    Proc Natl Acad Sci U S A; 2022 Apr; 119(16):e2121918119. PubMed ID: 35412886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A promising chemical series of positive allosteric modulators of the μ-opioid receptor that enhance the antinociceptive efficacy of opioids but not their adverse effects.
    Pryce KD; Kang HJ; Sakloth F; Liu Y; Khan S; Toth K; Kapoor A; Nicolais A; Che T; Qin L; Bertherat F; Kaniskan HÜ; Jin J; Cameron MD; Roth BL; Zachariou V; Filizola M
    Neuropharmacology; 2021 Sep; 195():108673. PubMed ID: 34153316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allostery at opioid receptors: modulation with small molecule ligands.
    Livingston KE; Traynor JR
    Br J Pharmacol; 2018 Jul; 175(14):2846-2856. PubMed ID: 28419415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Advances in the Realm of Allosteric Modulators for Opioid Receptors for Future Therapeutics.
    Remesic M; Hruby VJ; Porreca F; Lee YS
    ACS Chem Neurosci; 2017 Jun; 8(6):1147-1158. PubMed ID: 28368571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships.
    Gregory KJ; Noetzel MJ; Rook JM; Vinson PN; Stauffer SR; Rodriguez AL; Emmitte KA; Zhou Y; Chun AC; Felts AS; Chauder BA; Lindsley CW; Niswender CM; Conn PJ
    Mol Pharmacol; 2012 Nov; 82(5):860-75. PubMed ID: 22863693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic Evidence for a Putative Conserved Allosteric Site on Opioid Receptors.
    Livingston KE; Stanczyk MA; Burford NT; Alt A; Canals M; Traynor JR
    Mol Pharmacol; 2018 Feb; 93(2):157-167. PubMed ID: 29233847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Positive Allosteric Modulators of µ Opioid Receptor-Insight from In Silico and In Vivo Studies.
    Bartuzi D; Kędzierska E; Kaczor AA; Schmidhammer H; Matosiuk D
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33187107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-Activity Relationship Studies of 6α- and 6β-Indolylacetamidonaltrexamine Derivatives as Bitopic Mu Opioid Receptor Modulators and Elaboration of the "Message-Address Concept" To Comprehend Their Functional Conversion.
    Obeng S; Wang H; Jali A; Stevens DL; Akbarali HI; Dewey WL; Selley DE; Zhang Y
    ACS Chem Neurosci; 2019 Mar; 10(3):1075-1090. PubMed ID: 30156823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.